openPR Logo
Press release

HMI-102 Drug Market Forecast and Analysis | HMI-102 for Phenylketonuria: Market Size Analysis and Competitive Landscape by DelveInsight

07-12-2023 08:54 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

HMI-102 Drug Market Forecast and Analysis

HMI-102 Drug Market Forecast and Analysis

(Albany, United States)//- The HMI-102 market forecast report provides an analysis of the HMI-102 market analysis and forecasts up to 2032 in the seven major markets (7MM). The comprehensive report provides an analysis of HMI-102 market potential and HMI-102 market share analysis in Phenylketonuria across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

The report also helps you to understand the HMI-102 clinical and commercial landscape along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, special designations, and commercial and development activities.

Download Sample Report to know the HMI-102 Market Share: HMI-102 Drug Market Forecast @https://www.delveinsight.com/sample-request/hmi-102-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

HMI-102 Report Key Features and Coverage

The report presents a thorough description of HMI-102's characteristics and its use for Phenylketonuria, offering valuable insights into its drug's market potential. The report provides rich insights with respect to the competition in the market, as other emerging products that are in the advanced stage of pipeline development for Phenylketonuria are expected to give tough market competition to HMI-102. It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the Phenylketonuria market, and this report will help to understand how HMI-102 is going to compete against other drugs.

HMI-102 Drug Summary

Homology Medicines is developing HMI-102, an experimental gene therapy aimed at treating phenylketonuria (PKU) in adults. This therapy is specifically designed to address the mutated PAH gene, which is responsible for PKU, and it is administered using a liver-targeting AAVHSC15 vector. HMI-102 consists of the AAVHSC15 vector containing the human PAH gene's coding sequence, which is regulated by a promoter designed to ensure continuous expression of PAH in the liver. The selection of AAVHSC15 as the foundation for this therapy is based on its affinity for the liver, where the normal production of PAH protein takes place.

Homology Medicines is currently conducting the Phase II dose expansion phase of a randomized, concurrently controlled clinical trial known as the pheNIX study.

In February 2022, the US FDA placed a clinical hold on Homology's pheNIX gene therapy trial of HMI-102 in adults with PKU. The hold was prompted by the need to modify risk mitigation measures in response to elevated liver function test results. The company had intended to provide an update once they received further clarification from the FDA, but no additional updates have been provided thus far.

Stay ahead of the competition by leveraging key insights and evolving trends in the HMI-102 Market @ https://www.delveinsight.com/report-store/hmi-102-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Why HMI-102 Market Report?

Leading HMI-102 for Phenylketonuria forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HMI-102
A thorough HMI-102 market forecast will help understand how the drug is competing with other emerging HMI-102
Get an analysis of the HMI-102 clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
The report also provides future market assessments for HMI-102 market forecast analysis for Phenylketonuria in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in Phenylketonuria.

Download the sample report to learn more about the evolving market dynamics @ https://www.delveinsight.com/sample-request/hmi-102-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related reports:

Phenylketonuria Market Report 2032

DelveInsight's "Phenylketonuria- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as well as the Phenylketonuria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Phenylketonuria Pipeline 2023

"Phenylketonuria Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onycholysis market. A detailed picture of the Onycholysis pipeline landscape is provided, which includes the disease overview and Onycholysis treatment guidelines.

Phenylketonuria Epidemiology 2032

DelveInsight's 'Phenylketonuria - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Phenylketonuria, historical and forecasted epidemiology as well as the Phenylketonuria trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Leading Reports by DelveInsight:
Asthma Diagnostic Devices Market
Chronic Obstructive Pulmonary Disease Treatment Devices Market
Airway Management Devices Market
Cough Assist Devices Market
Pulse Oximeters Market
Hemodialysis Catheter Devices Market
Chronic Spontaneous Urticaria Market
Gender Dysphoria Market
Germany Healthcare Outlook
Biopsy Devices Pipeline Insight
Bacterial Conjunctivitis Market
Infliximab Biosimilar Insight
Eosinophilic Asthma Market
Cushing Syndrome Market
Functional Dyspepsia Market
Peripherally Inserted Central Catheters (PICC) Devices Market

Consulting Services:
DelveInsight's Healthcare Consulting Services offers a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.

By leveraging DelveInsight's deep industry knowledge, extensive market research capabilities, and advanced data analytics, healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight's consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.

Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals @ https://www.delveinsight.com/consulting

Tags:

FDA News for HMI-102, HMI-102 Drug, HMI-102 Drug Analysis, HMI-102 Drug Company, HMI-102 Drug Competitive Landscape, HMI-102 Drug Demand, HMI-102 Drug in US, HMI-102 Drug Market, HMI-102 Drug Market Analysis, HMI-102 Drug Market Size, HMI-102 Drug Sales, HMI-102Drug Market Forecast

Contact Us:

Kritika Rehani
+91-9650213330
Email: info@delveinsight.com
https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HMI-102 Drug Market Forecast and Analysis | HMI-102 for Phenylketonuria: Market Size Analysis and Competitive Landscape by DelveInsight here

News-ID: 3125437 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase